Other clinical data also showed that elevated CRP level is associated with poorer OS of RCC patients [30, 31] and CRP has a significant impact on OS of metastatic RCC patients treated with a tyrosine kinase inhibitor, either sunitinib or sorafenib [32, 33]. This evidence concerns the gene CRP and renal cell carcinoma.